Medicinal Chemistry of Hybrids for Neurodegenerative Diseases

Elisa Uliassi, Federica Prati, Salvatore Bongarzone, Maria Laura Bolognesi

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

Introduced more than 50 years ago, molecular hybridization remains one of the most rewarding approaches when searching for new molecules against neurodegeneration. This is because hybrids ligands, which finely integrate two pharmacophoric functionalities, are inherently more adequate to face the complex and multifactorial nature of such maladies. Indeed, both Alzheimer's disease and prion diseases are multifactorial neurodegenerative disorders with several target proteins contributing to their etiology. In this chapter we discuss selected examples of hybrid compounds rationally designed to hit more than one target involved in the neurotoxic cascade, which may hold great promise for the development of new and effective drugs. There are several medicinal chemistry challenges to overcome, but the potential benefits are worth the efforts.

Original languageEnglish
Title of host publicationDesign of Hybrid Molecules for Drug Development
EditorsMichael Decker
PublisherElsevier Inc.
Pages259-277
Number of pages19
ISBN (Electronic)9780081011188
ISBN (Print)9780081010112
DOIs
Publication statusPublished - Apr 2017

Keywords

  • Alzheimer's disease
  • Clioquinol
  • Donepezil
  • Framework combination
  • Lipoic acid
  • Neurodegeneration
  • Prion diseases
  • Quinone
  • Tacrine

Fingerprint Dive into the research topics of 'Medicinal Chemistry of Hybrids for Neurodegenerative Diseases'. Together they form a unique fingerprint.

  • Cite this

    Uliassi, E., Prati, F., Bongarzone, S., & Bolognesi, M. L. (2017). Medicinal Chemistry of Hybrids for Neurodegenerative Diseases. In M. Decker (Ed.), Design of Hybrid Molecules for Drug Development (pp. 259-277). Elsevier Inc.. https://doi.org/10.1016/B978-0-08-101011-2.00010-6